OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Geriatric Cataract

Submission Deadline: October 30, 2021 (Open) Submit Now

Guest Editor

Michele Lanza, MD

Associate Professor, Multidisciplinary Department of Medical, Surgical and Dental Sciences, Università della Campania Luigi Vanvitelli, Napoli, Italy

Website | E-Mail

Research Interests:  Optometry and vision science; glaucoma; eyes; cataract surgery; clinical ophthalmology; eye diseases; optical coherence tomography; retinal diseases; vision science; OCT

About This Topic

Cataract, the opacification of the human eye lens, leads to a reduction of visual acuity and is largely, diffused among adults, affecting almost one hundred million people worldwide.

The only effective therapy for cataract is surgery and, currently, the standard treatment is phacoemulsification with intraocular lens (IOL) implant in the capsular bag.

Improvements in instrumentation, technology, training programs, surgical techniques, design of intraocular lenses, and medications have led cataract surgery to become a very safe and effective procedure, able to restore visual acuity and to improve quality of life. Consequently, the expectations of patients shifted from the need of restoring vision, with or without spectacles, to the demand of obtaining a very good visual acuity, without spectacles, and being disappointed in case of discomfort consequent to the surgical procedure.

Innovations and new tools are available are going to be in order to provide always better results in these patients.

A great effort is produced also in developing new IOL able to improve not just the far visual acuity but also to provide improvements in near vision and in the overall quality of vision.

The purpose of this special issue is to provide physicians information about last update in every topic of cataract disease from the diagnosis to the post-operative management.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!